Video

Dr. Martin on the Frontline Treatment Landscape of MCL

Peter Martin, MD, discusses the frontline treatment landscape of mantle cell lymphoma.

Peter Martin, MD, chief, the Lymphoma Program, Meyer Cancer Center, associate professor of medicine, Weill Cornell Medicine, discusses the frontline treatment landscape of mantle cell lymphoma (MCL).

Unlike other lymphoma subtypes, there is not an established first-line standard of care in MCL, says Martin. Instead, there is a series of available options to select from.

Generally, younger, fitter patients are given intensive therapy, whereas older patients or those with multiple comorbidities are likely to receive less intensive chemoimmunotherapy regimens, explains Martin. 

The ultimate goal of therapy is to minimize the burden of the disease and maximize the patient’s quality of life, concludes Martin. 

Related Videos
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center